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Different results have been reported on the expression of 
epidermal growth factor receptor (EGFR) in human melano-
cytic lesions, which may be due to different methodologic 
approaches. Therefore, we compared EGFR expression in six 
human melanoma cell lines by utilizing the monoclonal anti-
bodies 2E9, 425, and 225, applying four immunocytochem-
ical staining procedures. The results were compared with 
those obtained by a multiple point ligand binding assay. In 
addition, Northern blot analysis was performed. 
A three-step immunoperoxidase method using the mono-
clonal antibody 2E9 proved most sensitive. Staining intensi-
ties, estimated semiquantitatively, correlated well with the 
quantitative data obtained by the ligand-binding assay. Ex-
pression on the mRNA level was also in agreement with 
these results. 
Immunohistochemical staining of a large series of human 
cutaneous melan<;>cytic lesions using the method selected 
showed differential EGFR expression in various stages of 
melanocytic tumor progression: 19% of common nevocellu-
lar nevi; 61 % of dysplastic nevi, 89% of primary cutane~Us 
melanomas, and 91 % of melanoma metastases showed staJU-
ing of the melanocytic cells. Intralesional heterogeneity of 
EGFR expression was present. Although the mean percent-
age of positive melanocytic cells in positive lesions did not 
increase with progression, mean staining intensity was 
stronger in malignant lesions compared to benign lesions. 
Ligand binding assays showed that EGFR expression in the 
highly metastasizing cell lines MV3 and BLM was at least 40 
times higher than in the cell lines IF6, 530, M14, and Mel57, 
which do not or only sporadically metastasize after subcuta-
neous inoculation in nude mice. Although the differences 
between the various stages of progression are not absolute, w.e 
provide further evidence that EGFR expression increases 1/ 
human melanocytic tumor progression. ] Invest Dermato 
99:168-173,1992 
---------------------------------------------------------------------------------------------------------
A ntigens associated with tumor progression of human melanocytic cells have been identified and are detect-able immunohistochemically [1- 7]. Different results have been reported on the expression in human me-lanocytic lesions of one of these antigens, the epider-
mal growth factor receptor (EGFR) [7,8]. 
The EGFR is a 170-kD transmembrane glycoprotein [9]. The 
cytoplasmatic domain of the receptor is in structure similar to the 
v-erbB oncogene protein [10]. Binding of epidermal growth factor 
(EG F) or transforming growth factor CI' to the external domain of 
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Abbreviations: 
ABC: avidine-biotine complex 
DN: dysplastic nevus 
EGFR: epidermal growth factor 'receptor(s) 
(m)EGF: (mouse) epidermal growth factor 
MM: melanoma metastasis 
MoAB: monoclonal antibody(s) 
ND: not determined 
NN: nevocellular nevus 
PAP: peroxidase - anti-peroxidase 
PM: primary melanoma 
RAMPO: peroxidase-labeled rabbit anti-mouse immunoglobulin 
EGFR can result in the activation of a mitogenic pathway [11]. III 
vitro, overexpression of the human EGFR confers an EGF-depeIl-
dent transformed phenotype to NIH 3T3 cells [12] . 
Elder et al [7] reported that the EGFR shows the distribution of a 
progression antigen in human melanocytic lesions. However, III 
another series of human melanocytic lesions studied immunohistO-
chemically by Real et al [8] no EGFR expression was found. As these 
authors used different immunohistologic techniques and differeIlJ 
monoclonal antibodies (MoAb), we wondered whether this coul 
explain the dissimilar results. Therefore, we first compared the se:;-
sitivity of four routinely applied immunohistochemical metho IS 
using a panel of six human melanoma cell lines with different \eve s] 
ofEGFRexpression. The MoAb used by Elderetal (MoAb 425) [13 
and by Real et al (MoAb 225) [14] were compared with a third one, 
MoAb 2E9 [15], which appeared very sensitive in a pilot study. I? 
addition, the level of EGFR expression in the cell lines was quanti-
fied using a multiple-point ligand-binding assay. Furthermot 
EGFR-mRNA expression was determined. Based on these resu tS 
the most sensitive immunohistochemical method was chosen for 
further study of EGFR expression in a large series of melanocytlr 
lesions. We provide further evidence for a differential expreSSiOn 0 
EGFR, both in human lesions of various stages of melanocytlC 
tumor progression and in human melanoma cell lines with a differ-
ent metastatic behavior in nude mice. 
MATERIALS AND METHODS 
Cell Lines Human melanoma cell lines used included the folio;; 
ing: IF6 [16]. 530 [17]. Mel 57 [18]. M14 [19], BLM [16], and M 
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[20] . Cell lines IF6, BLM, and MV3 were developed in our labora-
tory. BLM is a subline of the BRO line [21] with a higher metastatic 
pOtential in nude mice than the parental line. Furthermore, the 
vulval carcinoma cell line A431 was used [22] . All cell lines were 
rown as monolayers in culture fl asks on Dulbecco's modified 
agle's medium supplemented with 10% fetal calf serum, gluta-
mlUe~ ~enicillin G, and Streptomycin. Cells were harvested by short 
tryPSll11zation and processed for cytospin preparation or RNA isola-
tlon. 
~ul1lan Melanocytic Lesions Subcentral representative slices 
16 common nevocellular nevi (NN), 13 dysplastic nevI (ON) , 48 rnmary cutaneous melanomas (PM), and 22 melanoma metastases 
yMM) were snap-frozen in liquid N 2 and stored at -70°C until use. 
he histopathologic diagnosis was made on corresponding paraffin 
Sections and the representativiry of the samples of the frozen sec-
tlons was ascertained. Primary melanomas were divided into three 
(~tegories according to the Breslow thickness [23]: ,.;0.76 mm 
hM1 ), between 0.76 and 3 mm (PM2) , and ~3 mm (PM3) in 
t Ickness. The degree of atypia in ON was assessed [24]. 
~oAb and Immunocytochemical Techniques MoAb in-
c[ uded 1) 2E9 (ascites fluid) [15]; 2) 425 (tissue culture supernatant) 
13L, 3) 225 (1 mg/ml purified immunoglobulins) [14] . All three 
mUnne MoAb recognize an antigenic determinant of the prNein 
~ore of the EGFR. Cytospin preparations of the cell lines were 
({I.ed, fixed in acetone, and incubated for 60 min with MoAb 2E9 
.25), MoAb 425 (undiluted), or MoAb 225 (1 : 12.5). The further 
procedure consisted of one of four different immunoperoxidase 
~:~hnlques : 1) ~ two-step method, incubation with peroxidase-Ia-
2 ed rabbit anti-mouse Ig serum (RAMPO, Dakopatts, D enmark); 
b) a three-step method, incubation with RAMPO followed by incu-
atlon with peroxidase-labeled swine anti-rabbit Ig serum (Dako-
patts, Denmark)' 3) a PAP method incubation with rabbit anti-
mo ' , .., 
Use Ig serum (Cappel, Belgium), followed by 111cubatIOn with 
sWlhne anti-rabbit Ig serum (Dakopatts, Denmark) and incubation 
Wit bb ' d) 'd' bio . ra It PAP complex (Dakopatts, Denmark); an 4 an aVI 111-
. tlU-complex (ABC) method (Vector Laboratories, USA) . All 
~cubations were performed at room temperature for 30 - 60 min. 
e~een incubations sections were rinsed with PBS. 
. hsuahzation of the immunoperoxidase reactions was performed 
Wit 3-amino-9-ethylcarbazole as substrate. Preparations were 
~unterstained with hematoxylin. Titration experiments with the 
~Ab were performed using method 2. 
d . ~sed on the staining results of the cytospin preparations, air-
~Ie and acetone-fixed frozen4-llm sections of melanocytic lesions 
d ere processed using MoAb 2E9 and the three-step immunoperoxi-
ase technique (method 2). 
Score TI ' . f .. . I I . 11 
scored :e 1I1ten slty 0 sta1l1111g 111 t 1e me anoc(ytlcdce s )was 
-t--t- ( SelUiquantltatively as - (none), ± (weak), + mo erate , or 
marked) . 
po In the cytospin preparations of the cell lines the percentages of 
th s~lve cells and the average staining intensities were estimated. In 
poe rozen sections of human melanocytic lesions the percentages of 
£~~Ive melanocytic cells were estimated. Lesions were regar~ed 
St . R POsitive if 5% or more of the melanocytic cells in the lesIOn 
all1ed. 
t!gand-Binding Assay Cells were harvested with a rubber po~ 
So eman and homogenized by means of ultrasound bursts (MSE 
secnlp~er- 150: nominal frequency 23 kHz, amplitude 10 11m) for 10 
7,4°n s, on ice, in EGFR assay buffer (0.02 M phosphate buffer, pH 
Thonta1l1l11g 0.15 M NaCI and 70 Ilg/ml Bacitracin). 
to S .e homogenates were centrifuged for 10 min at 800 X g, 4°C, 
tantn down nuclei and other coarse cell fragments. The superna-
me shere recentrifuged for 60 min at 105,000 X g, 4°C. The cell-
£G~rane pellets thus obtained were resuspended in 1.1 ml of 
pert assa~ buffer by means of ultrasound bursts. EGFR assays were 
SUm ormed In a manner similar to that described previously [25] . To 
tio
n 
~nze: eight times 100 III aliquots of cell-membrane prepara-
ere I11cubated with 125I-mouse-EGF (mEGF) tracer at con-
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Table I. Expression of EGFR Protein and EGFR mRNA in 
Human Melanoma Cell Lines and Cell Line A431 
A' 
Two-Step Three-Step 
Method Methodb 
Cell Line 425 225 2E9 425 225 2E9 B' C' 
IF6 
530 ± 10.5 ± 
M14 ± 33.9 ± 
Mel 57 
BLM + + + ++ 1436 ++ 
MV3 + + + ++ 1480 ++ 
A431 ND ND ND ND ND +++ 17271 +++ 
• A, EGFR expression as detected immunohistochemically using the monoclonal 
antibodies 425 , 225, and 2E9. B, EGFR expression in fmol per mg of cell membrane 
protein as determined w ith a ligand binding assay. C, EGFR mRNA expression deter-
mined by Northern blo t analysis. 
b Same scores were obtained using the three srep, the PAP, or the ABC method. 
, - , not detectable « 6 fmol/mg). 
J -, no signal; ±, faint signal; ++, marked signal; +++, strong signal. 
centrations ranging from 0.15 to 3.5 nM. Aspecific binding was 
assessed in duplicate using 1 nM 1251_mEGF and a 250-times excess 
of unlabeled mEGF. Receptor-bound and free ligand were separated 
using hydroxyapatite. Receptor values were calculated by Scatchard 
analysis and expressed in fmol/mg of membrane protein. 
Northern Blot Analysis Total RNA of the cell lines was isolated 
by the LiCl/urea method [26] . Ten-microgram aliquots of total 
RNA were glyoxylated [27] and size fractionated on a 1 % agarose 
gel fo llowed by blotting on hybond-N-membrane according to the 
procedure recommended (Amersham, UK). 
Hybridizations were performed as described [28]' To detect 
EGFR mRNA the 0.8-Kb EcoRI fragment of Lambda HER A 64 
was used as a probe [29]. For control hybridizations on the amount 
of RNA a 28S rRNA probe was used. Both probes were radiolabeled 
using the multiprime labeling method (Amersham, UK) . 
RESULTS 
Immunocytochemistry of the C ell Lines Table I (columns A) 
summarizes data on the EG FR expression in the melanoma cell lines 
and cell line A431 as obtained by applying different MoAb and 
immunocytochemical staining techniques. For each separate 
MoAb, the intensities of the staining signals were similar when 
comparing the three-step immunoperoxidase technique, the PAP 
technique, and the ABC technique . The two-step technique was 
less sensitive. With regard to the MoAb used at the indicated dilu-
tions, a less insensitive or negative staining result was obtained with 
MoAb 425 and MoAb 225, compared with MoAb 2E9. Titration 
experiments showed similar staining signals for the MoAb 2E9, 
425, and 225, when used diluted 1: 300, undiluted, and diluted 
1: 12.5, respectively. Using the MoAb 2E9 (1 : 25) and the three-
step immunoperoxidase detection method, cell lines IF6 and Mel 57 
were negative, 530 and M14 weakly positive, and BLM and MV3 
markedly positive (Fig 1A - C). The positive reference cell line 
A431 showed a very strong staining. In the positive melanoma cell 
lines 80 - 100% of the tumor cells stained. 
Ligand-Binding Assay of the Cell Lines In Table I (lane B) 
and Fig 2 of the level of EGFR expression in the cell lines, as 
quantified by radioligand-binding assays is shown. Cell line A431 
showed a very high expression. Cell lines MV3 and BLM showed a 
high, cell lines M 14 and 530 a low, and cel l lines IF6 and Mel 57 no 
measurable level of expression. All the EGFR containing melanoma 
cell lines showed one single class of high-affiniry EGFR binding 
sites. In contrast to this, the A431 cell line, containing high levels of 
EGFR, showed a curvilinear Scatchard-plot (linearized in Fig 2), 
indicating the presence of two EGFR binding sites w ith different 
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D. 
Figure 1. EGFR expression in human melanoma cell lines (A - C, cytospin preparations) and human melanocytic lesions (D - G, frozen sections). rmmunocy; 
tochemical sta ining using the monoclonal antibody 2E9 and a three-step detection method. A, cell line IF6 showing no staining, as also found in cell ~ l~ 
Mel57; B, cell line M 14 showing weak staining, as also found in cell line 530; C, cell line BLM showing marked staining, as also found in cell line MV3, I ~ 
common nevocellu lar nevus; negative control; the primary MoAb 2E9 was omitted; E, common nevocellular nevus, nevus cells show no staining, ~ ld 
epidermis shows a marked staining; F, common nevocellular nevus, nevus cells show a weak staining in a diffuse pattern, the epidermis shows a Olaf e e 
staining, the mean staining intensity observed in positive dysplastic nevi was similar to the staining show n here; G, primary cutaneous melanoma, ddfusp 
intermed:ate to marked staining of melanoma cell s, the mean staining intensity observed in the positive melanoma metastases was similar to the staining show 
here. Scale bar, 50 }lm. 
affinity. The quantitative ligand-binding - assay data on EGFR ex-
pression in the cell lines correlated well with the semiquantitative 
immunocytochemical results obtained with the MoAb 2E9 using a 
three-step detection method. This correlation was not found with 
the MoAb 425 and the MoAb 225 (Table I). 
Northern Blotting of the Cell Lines EGFR gene transcripts 
(10. 5 and 5.8 Kb) were present in four of six human melanoma cell 
lines tes ted (Fig 3, table I (lane C) ]. Cell lines BLM and MV3 
showed a high (+ +), M14 and 530 a low (± ), and IF6 and Mel 57 no 
detectable (-) level of EGFR-mRN A expression. Cell line A431 
showed a very high EGFR mRNA expression (not shown) . r~~ 
results on the EGFR expression in the cell lines, as detected w~th ~he 
MoAb 2E9 using the three-step technique, correlated well wlth 
EGFR-mRNA levels in the same cell lines . 
Immunohistochemistry ofMelanocytic Lesions The ~J(p[es~ 
sion of the EG FR in frozen sections of the melanocytic les!On~ a r 
assessed immunohistochemically is summarized in T able 2A . . oh 
the different categories it shows the percentage of lesions in whle d 
;?: 5% of the melanocytic cells stained. As in the cell lines M 14 a~_ 
530 there was a good correlation between the weak immunocyt 
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Figure 2. EGFR expression in human melanoma cell lines and cell line 
A431. Scatchard plot of data obtained with a ligand-binding assay. The 
°hdlnate intercept depicts the level of EGFR expression in fmol/ml. Note 
t e scale difference between A and B. 
~~iC stai.ning, the ligand-binding~assay data, and the mRNA level, 
ak staining in the sections was regarded as relevant and taken mto 
aCCOUnt. 
be A. clear difference was seen in EGFR expression, when compa.ri.ng 
I nlgn and malignant lesions (Table II). The percentage of posItive 
eSIOns was 19 for common nevocell ular nevi, 89 for primary mela-
nOmas, and 91 for melanoma metastases. The dysplastic nevi hold 
ar Int~rmediate position (61 %). In primary melanomas th~re was. no 
~ ear Increase in the number of positive lesions with mcreasmg 
res low thickness. Within the group of dysplastic nevi there was no 
h?rrelation between a history of dysplastic nevus syndrome or the 
Istologlc degree of atypia and EGFR expression. . 
I Beterogeneity of EGFR expression was observed in most leSIOns. 
nlfach category of lesions the percentage of positive melanocytlc 
Ce s per lesion varied (Fig 4). With regard to this parameter there 
Was no correlation with the stage of progression (Table 2B). Com-
panng th d'G: . 1 . . . 'ty . 
. . e Inerent categones, t Ie average sta1l1111g mtensl 111 
POSitive nevi was weak in primary melanomas and metastatic mel a-
nOm . , 
as Intermediate to marked (Fig 1D~ G). 
DISCUSSION 
In thi d . . . h S stu y we have compared the level ofEGFR expression 111 SIX 
chma.n melanoma cell lines using three MoAb, four immunocyto-
N emlcal techniques, a multiple-point ligand-binding assay, and A~~thern blot analysis. The level of EGFR expression in celll~ne 
e 1·1, used as a control was very high which is in agreement With at ler [ , . ' . f GFR Id be d reports 8,15,29]. A relatively low expressIOn 0 E cou 
th etected immunocytochemically only when MoAb 2E9 and a 
t .ree-step staining method were used. Semi-quantitative data ob-
alned w' h h' . . d II . I I q It t IS most sensItive approach correlate we Wit 1 tIe 
bluantative data obtained with the ligand-binding assay. Northern 
Otting I . W res~ ts were also m concordance. 
n e quantified the differences in EG FR expression between mela-
[106m] a cell lines with a different metastatic behavior in nude mice 
ta . (Cellltnes that frequently give rise to spontaneous lung metas-ass~h BLM and MV3) had a high level ofEGFR expression, where-
111 Ose with no (IF6 and 530) or only a low (M14 and Mel 57) 
etastati . I h bl I I If' 1'h c potentia ad no detecta e or a ow eve 0 expressIOn. 
be eSi data suggest that an increased level ofEGFR expression may 
tai~e ;vant in melanocytic tumor progression. Supporting data, ob-
and \ With other cell types, come from studies by Di Fiore et al [12] 
31'3 elu et al [30], who found a transformed phenotype of NIH 
ex ~e\ls after induction of EGFR overexpression by transfection 
penments and from a report by Wells et al [31] who described a 
CD 
U. 
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Figure 3. Northern blot analysis of EGFR mRNA expression in human 
melanoma cell lines using the 0.8-Kb fragment oflambda HER 64 as a probe. 
Two bands (10.5 and 5.8 Kb) are visible in cell lines BLM and MV3 (intense) 
and in cell line 530 and M14 (faint). No band could be detected with the cell 
lines IF6 and Mel 57. As a control on the amount of RNA, the blot was 
re-hybridized with a 28S-rRNA probe. As molecular weight marker lambda 
DNA digested with endonuclease Hind III was used. 
transformed phenotype of NR6 cells expressing a transfected non-
internalizing mutant EGFR. 
Because of the good correlation with the ligand-binding ~ assay 
results , we considered a weak immunocytochemical staining, as 
obtained in the cell lines 530 and M14 with MoAb 2E9 and a 
three-step method, as specific and relevant. This is underscored by 
the fact that cell lines IF6 and Mel57 were EGFR negative with 
both techniques. 
By doing so, we found differential EGFR expression in benign, 
premalignant, and malignant human melanocytic lesions. About 
20% of common nevocellular nevi, 60% of dysplastic nevi, and 90% 
of primary and metastatic melanoma lesions showed staining in at 
A' 
Bd 
NN 
19 
45 
Table II. Expression of EGFR in 
Human Melanocytic Lesionsa 
DN 
61 
67 
Categoryb 
PM1 
87 
56 
PM2 
85 
36 
PM3 
95 
42 
MM 
91 
60 
• EGFR expression as detected inununohistochemically (MoAb 2E9, three-step 
method). 
• NN, common nevoccllular nevus; ON, dysplastic nevus; PM I , primary melanoma 
(Breslow :50.76 mm); PM2, primary melanoma (Breslow between 0.76 mm and 
3 mm); PM3, primary melanoma (Breslow «3 mm); MM, melanoma metastasis. 
, A, percentage of positive lesions per category. 
J B, mean of percentages of positive melanocytic cells in positive lesions per category. 
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PERCENTAGE POSI'l'IVE MELANOCYTIC CELLS 
8 1- 100 
5 1 - 80 
3 1 - 5 0 
11- 3 0 
5 - 10 
<5 
NN DN PM1 PM 2 PM 3 MM 
CATEGORIES 
Figure 4. Diagram showing heterogeneity of EGFR expression in human 
melanocytic lesions, based on immunohistochemical staining using the 
monoclonal antibody 2E9 and a three-step detection method. Each dot repre-
sents the estimated percentage of melanocytic cells stained in one lesion. 
Lesions are ordered by category. NN, common nevocellular nevus. ON, 
dysplastic nevus. PM1, primary melanoma (Breslow :50.76 mm). PM2, 
primary melanoma (Breslow between 0.76 mm and 3 mm). PM3, primary 
melanoma (Breslow 2: 3 mm). MM, melanoma metastasis. 
least 5% of the melanocytic cells. Two previous reports have dealt 
with EGFR expression in human melanocytic lesions [7,8]. Al-
though Real et al [8] were able to detect EGFR expression in 19 of 
36 melanoma cell lines by rosetting-assay analysis, they could not 
detect EGFR expression in five of five primary melanoma lesions 
and seven of seven metastases immunohistochemically, using 
MoAb 225 and an ABC procedure. Elder et al [7] detected EGFR 
immunohistochemically in two of 11 dysplastic nevi, in three of 16 
radial-growth - phase primary melanomas, in eight of nine vertical-
growth-phase primary melanomas, and in eight of 10 metastases, 
using a PAP procedure and MoAb 425. Mature dermal nevi were 
found negative. 
The discrepancy between our results and those of Real et al [8] 
might be due to the different antibodies used, as equally sensitive 
immunohistochemical procedures for the detection of EGFR were 
applied. Our results suggest that the MoAb 225 may have a lower 
avidity than MoAb 2E9. A factor that may be of major importance is 
the fact that the two MoAb recognize different epitopes [32] . For 
the detection of the EG FR expression in melanoma cell lines Real et 
al used a highly sensitive rosetting assay and found a positive reac-
tion in about half of the lines, which is in agreement with our 
results. The differences in tissue distribution of EGFR, reported by 
Elder et al [7] and in the present study, might also be explained by 
the fact that different MoAb were used. In our comparison of MoAb 
and detection methods on a panel of melanoma cell lines, we found 
for the equally sensitive three-step and PAP procedures that the 
staining signal obtained using MoAb 2E9 was stronger than that 
using MoAb 425. In addition, the positive correlation between the 
staining signal obtained with MoAb 2E9, the EGFR level as deter-
mined by ligand-binding analysis, and the level of mRNA expressed 
was not found for MoAb 425. MoAb 2E9 was used as ascites fluid 
and the MoAb 425 as tissue-culture supernatant. We assume that 
the concentration and the avidity of the MoAb used have influenced 
the staining results. Furthermore, the MoAb may recognize differ-
ent epitopes [13,15]. The outcome of our study of melanocytic 
lesions was not altered essentially when a 10% margin was applied 
to score a lesion as "positive." If only the lesions showing a staining 
intensity of + or more would be regarded relevant, thus excluding 
the weak-staining signals, no benign and fewer premalignant le-
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
sions would be scored positive. However, we were unable to detect 
differential staining in horizontal-growth - phase primary melan-
omas as compared to vertical-growth - phase primary melanomas, as 
reported by Elder et al [7]. 
From this study we conclude that, although the differences ?e-
tween the various stages of progression are not absolute, we prOVIde 
further evidence that EGFR expression increases in human melano-
cytic tumor progression. 
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